Human Airway and Alveolar Organoids from BAL Fluid Liu, Monica Yun; Chen, Belinda; Borji, Mehdi ...
American journal of respiratory and critical care medicine,
06/2024, Letnik:
209, Številka:
12
Journal Article
We read with interest the editorial “Clinical remission with biologic therapies in severe asthma: a matter of definition” 1. We absolutely agree that the definition of clinical remission is of ...critical importance, and as with rheumatology, gastroenterology and dermatology, this is likely to be an iterative process. Early intervention with targeted treatments has been associated with an improvement in quality of life and decreased symptom burden in these non-respiratory inflammatory diseases, and certainly the onus to provide prospective evidence showing improved quality of life and disease outcomes with early intervention and sustained remission in severe asthma now lies with the severe asthma community.
There is currently no evidence to support the use of maintenance and reliever therapy (MART) in patients with severe asthma and persistently elevated T2 biomarkers despite adherence to high dose ICS treatment
https://bit.ly/42IOVbA
We agree with P.J. McDowell and co-workers that the patients whose data are recorded in the UK Severe Asthma Registry (UKSAR) have, on average, more severe asthma than participants in randomised ...controlled trials (RCTs) of inhaled corticosteroid (ICS)/formoterol maintenance and reliever therapy (MART) 1, 2. However, poor generalisability from RCTs to severe asthma registries is also the case for RCTs of high dose ICS/long-acting β-agonist (LABA) plus short-acting β-agonist (SABA) reliever therapy. There are similar differences in average baseline severity between patients in the UKSAR database and participants in RCTs of high dose
versus
medium dose ICS/LABA plus SABA therapy, as with those in the MART studies (table 1) 3–13.
ICS/formoterol MART is an evidence-based alternative to high dose ICS/LABA in asthma patients at high risk of severe exacerbations; limited generalisability of RCTs to severe asthma registries applies similarly to high dose ICS/LABA therapy as to MART
https://bit.ly/4aVFrNH
Letter to the Editor in Response to Zhou et al Troth, Sean; Butterton, Joan; DeAnda, Carisa Stadlman ...
The Journal of infectious diseases,
10/2021, Letnik:
224, Številka:
8
Journal Article
PDF